

Figure 1




Figure 2





Figure 3

Immunolabeling for α -SMA










Figure 4

control

cCAF

N-peptide











Figure 5




Figure 6





Figure 7



control (day 0)



cCAF (day 0)



control (day 3)



cCAF (day 3)





Figure 8








Figure 9



Summary of cCAF/Peptide effects on cCXCR1




Figure 11